While clients have told us that it is as if Strategy Inc. can see the future, it is the rigorous diligence and experience that uncovers the insight that provides strategic intelligence

Investors and purchasers seek technology that affects the overall cost of care, such as prevention from hospital admittance or readmittance, in addition to the pressure to reduce treatment costs and avoid retreatments, or move treatment to less costly locations for episodes of care such as the clinic or home.

Strategy, Inc. also helps technology innovators to strategically identify market inroads. Recently, a company reached out, considering adding a fully revolutionary product category to their portfolio and sought to expand their understanding of the future therapeutic landscape, current competitors, and alternate solutions that could end up being competitors. They hired Strategy Inc. to dive deep into potential adoption, end-user needs, and treatment challenges that by solving might give them a competitive advantage. Nancy mentions, “While clients have told us that it is as if Strategy Inc. can see the future, it is the rigorous diligence and experience that uncovers the insight that provides strategic intelligence.”

Now tasked with supporting companies in the health reform era where facilities are charged with cost control, healthcare leadership is required to be more diligent than ever in formulary selection. Healthcare facilities have most all implemented Value Analysis Committees that include hospital supply chain, physicians and other healthcare providers along with administrators to approve their technology offerings through an evaluation process that compares emerging technology to existing solutions in terms of safety, efficacy, cost, outcomes and other delimiters as the final hurdle. Where once the market required a technology that addressed a significant unmet need with a safe and effective solution and regulatory approval, now we also see a request for evidence from target users and hospital systems of how the technology will lower costs and improve outcomes. Strategy Inc. considers the hurdles of the value analysis review process in their consulting and go to market strategies by performing a robust competitive positioning analysis, outlining the specific documentation that will be required by clinical area and performing a commercialization strategy on the specific technology to discuss the required components for a successful launch.

Strategy Inc. supports all strategic advisement with rigorous research. It is the key to their success. Determining the opportunities and the optimal strategies requires a comprehensive evaluation, industry experience, an in-depth understanding of the range of factors that impact success. Market analysis is an iterative process as ongoing evaluation of the business may identify additional opportunities for existing products and services, either during their growth phase or even as they mature.

Nancy has also recently contributed several chapters as an invited author in a Lippincott book on commercializing medical innovation and is also doing so for Elsevier. Insight can be garnered on her methods in these books.

Nancy is an immunologist and also has an MBA.